Meet Our Board


Mr Peter Francis LLB, Grad Dip (Intellectual Property)

Non-Executive Chairman

Mr Peter Francis is a partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to a large number of corporations and research bodies. 

Other Current Directorships of Listed Companies
Optiscan Imaging Limited 
Former Directorships of Listed Companies in last three years
None

 

Appointed February 2006


Dr John Chiplin PhD

Non-Executive Director

Dr John Chiplin is a founder of and has served as a Managing Director of investment company, Newstar Ventures Ltd., since 1998. More recently, he has served as a director of Medistem, Inc. through its acquisition by Intrexon Corporation in 2014, as founding Chief Executive Officer of Arana Therapeutics Limited from 2006 through its acquisition by Cephalon, Inc. in 2009, as director of Domantis Ltd through its acquisition by GlaxoSmithKline plc in 2006, and as Managing Director of ITI Life Sciences Fund from 2003 to 2005. He currently serves on the board of directors of Adalta Pty Ltd, Batu Biologics Inc., Cynata Therapeutics Limited (CYP.AX), Prophecy Inc., ScienceMedia Inc., Scancell Holdings plc (SCLP.L, Executive Chairman), Sienna Cancer Diagnostics and The Coma Research Institute.  

John's Pharmacy and PhD degrees are from the University of Nottingham, Nottingham, United Kingdom.  

Other Current Directorships of Listed Companies
Cynata Therapeutics, Scancell Holdings plc

Former Directorships of Listed Companies in last three years

Calzada Ltd. and Medistem Inc.


 

Appointed February 2010


Mr J. Kevin Buchi BA (Chem), MBA, CPA

Non-Executive Director

Mr. Buchi currently serves as the CEO of TetraLogic Pharmaceuticals a public U.S. Biotechnology company.  Prioir to that, Kevin served as Chief Executive Officer (‘CEO’) of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (‘Teva’) in October 2011. After the acquisition he served as Corporate Vice President, Global Branded Products of Teva. Kevin joined Cephalon, Inc. in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.

Other Current Directorships of Listed Companies

Tetralogic Pharmaceuticals Corporation  


Former Directorships of Listed Companies in last three years

Stemline Therapeutics, Inc., Forward Pharma A/S, Alexza Pharmaceuticals and Epirus Biopharmaceuticals, Inc.

 

Appointed April 2013


Ms Megan Boston B.Comm, CA, GAICD, Grad Diploma Share Trading

Non-Executive Director

Megan Boston is formerly the Managing Director of Omni Market Tide, a listed technology company specialising in shareholder communications, investor relations and voting.  Megan holds a Bachelor of Commerce and is a Chartered Accountant with over 10 years’ experience as a non-executive Director across a range of industries.  She has chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Megan has completed the Company Directors Course Diploma run by the Australian Institute of Company Directors.  Previously, Megan held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers.

Other Current Directorships of Listed Companies
None

Former Directorships of Listed Companies in last three years

Omni Market Tide Limited (ASX).


 

Appointed August 2016


Dr Jerel A Banks M.D., Ph.D.

Non-Executive Director

Jerel has been a director since October 25, 2016.  Dr. Banks is the Chief Investment Officer of Nant Capital, LLC.  Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015.  During his time as portfolio manager and research analyst the assets under management for the Franklin Biotechnology Discovery Fund reached $5 Billion (USD). Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology equity research analyst at Sectoral Asset Management from 2011-2012.  Sectoral Asset Management, a healthcare-focused global investment management company, managed a family of investment portfolios with total assets under management of $3 Billion (USD).  From 2008-2011, Jerel worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas.  Jerel began his career in investment management as a healthcare equity research associate at Capital Research Company, and he was a member of the equity research team from 2006-2008.  Capital Research Company is the investment management company for the American Funds family of Mutual funds, and the assets under management exceed $1 Trillion (USD).  Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University.

Other Current Directorships
Genos Research, Inc. 

Former Directorships (last 3 years)
None


 

Appointed October 2016